Bexion Pharmaceuticals announced that the Food and Drug Administration (FDA) has granted Orphan Drug designation to Saposin C, the active ingredient in BXQ-350 for the potential treatment of glioblastoma multiforme.

In pre-clinical studies, Bexion’s first-in-class biologic, BXQ-350 has shown promising results in selectively inducing cell death in the laboratory. BXQ-350 is a proprietary nanovesicle formulation of Saposin C (sphingolipid activator protein C, or SapC) and the phospholipid dioleoylphosphatidylserine (DOPS).

RELATED: Cancer Patients Rarely Demand Unnecessary Treatment, Tests

Previously, Bexion was awarded a Phase 2 Bridge Award (Small Business Innovation Research Grant) from the National Cancer Institute (NCI) to support the manufacture and clinical testing of BXQ-350.

For more information visit